Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.58 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.58 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.58 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.58 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | REN | P00797 | 4/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404739 | 1.00 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5387761 | 0.90 | KLK5 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5387766 | 0.90 | KLK5 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5223341 | 0.86 | KLK5 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5217566 | 0.86 | KLK5 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5217575 | 0.86 | KLK5 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5223349 | 0.86 | KLK5 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30318975 | 0.85 | BCHE (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10722184 | 0.85 | BCHE (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1104912 | 0.85 | KLK5 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | PSEN1 4/4885PSEN2 2/4885APH1B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.